| Autor: |
Sørensen PG, Rørth M, Hansen HH, Dombernowsky P, Høst H |
| Jazyk: |
angličtina |
| Zdroj: |
European journal of cancer & clinical oncology [Eur J Cancer Clin Oncol] 1983 Jan; Vol. 19 (1), pp. 25-7. |
| DOI: |
10.1016/0277-5379(83)90392-9 |
| Abstrakt: |
A phase II trial has been performed in squamous cell carcinoma of the lung using peplomycin. This compound is a bleomycin analogue with less pulmonary toxicity and a broader antitumor effect than bleomycin in experimental animal systems. Twenty-one evaluable patients were treated using a dose schedule of 5 mg/m2 twice weekly intravenously. None of the patients had previously received radiation or chemotherapy. The median dose of peplomycin received was 160 mg (range 45-254). One patient obtained a partial remission lasting 3 months. One out of 21 patients developed clinical symptoms and a decrease in the lung function test performed during treatment indicative of toxicity. Other manifestations of toxicity are comparable to those of bleomycin. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
